ALKS
Alkermes plc
NASDAQ · IEHealthcareBiotechnology
$51.72-1.90%
Price as of Jul 20, 2026
ALKS growth
Alkermes plc growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +3.2%
- EBITDA
- -40.8%
- EBIT
- -50.9%
- EPS
- -56.7%
- Free cash flow
- -53.9%
- Operating cash flow
- -50.4%
Forward estimates
- Revenue
- +17.6%
- EBITDA
- +33.9%
- EPS
- -90.3%
Three-year CAGR
- Revenue
- +9.9%
- EBITDA
- +76.9%
- EBIT
- -21.7%
- Net income
- -17.6%
- EPS
- -17.1%
- Free cash flow
- +16.6%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.